← Back to Search

Virus Therapy

Bacteriophage Therapy for UTI

Phase 1 & 2
Waitlist Available
Led By Robert J Hopkins, MD
Research Sponsored by Adaptive Phage Therapeutics, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 1 year
Awards & highlights
No Placebo-Only Group

Summary

This trial is testing a treatment that uses viruses to kill bacteria in patients with urinary tract infections. It focuses on people with infections caused by E. coli and K. pneumoniae, including those with recurring or complicated cases. The goal is to see if this treatment can safely and effectively clear the infection. Bacteriophage therapy has shown potential as an effective and safe treatment for urinary tract infections, but there is a lack of comprehensive studies.

Eligible Conditions
  • UTI

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Identify ideal bacteriophage treatment regimens based on improvements in disease control rates
Secondary study objectives
Phage Therapy
Assess the tolerability of bacteriophage therapy
Other study objectives
Recurrence of urinary tract infection

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

6Treatment groups
Experimental Treatment
Group I: Subcohort DExperimental Treatment1 Intervention
Selected phage for Klebsiella pneumoniae administered via selected route based on previous arms.
Group II: Subcohort CExperimental Treatment1 Intervention
Selected phage for E. coli administered via selected route based on previous Arms.
Group III: Subcohort BExperimental Treatment1 Intervention
Selected phage for Klebsiella pneumoniae administered via selected route based on previous Arms.
Group IV: Subcohort AExperimental Treatment1 Intervention
Selected phage for E. coli administered via selected route based on previous Arms.
Group V: Intravesical (IVS)Experimental Treatment1 Intervention
Phage administered via the intravesical route.
Group VI: Intravenous (IV)Experimental Treatment1 Intervention
Phage administered via the intravenous route.

Find a Location

Who is running the clinical trial?

Adaptive Phage Therapeutics, Inc.Lead Sponsor
5 Previous Clinical Trials
126 Total Patients Enrolled
United States Department of DefenseFED
908 Previous Clinical Trials
333,679 Total Patients Enrolled
Robert J Hopkins, MDPrincipal InvestigatorChief Medical Officer
1 Previous Clinical Trials
~0 spots leftby Nov 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top